Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 4:13 AM
Ignite Modification Date:
2025-12-25 @ 4:13 AM
NCT ID:
NCT06956820
Eligibility Criteria:
In order to be eligible to participate in this study, a subject must meet all of the following crite-ria:
* Polypharmacy defined as the use of 5 or more drugs
* Start usage of at least one index drug according to the list in table 3.
* Subject must be ≥ 18 years old
* Subject is able and willing to take part and be followed-up for at least 12 weeks
* Subject is able to donate blood or saliva
* Subject has signed informed consent
A potential subject who meets any of the following criteria will be excluded from participation in this study:
* Pregnancy or lactating
* Life expectancy estimated to be less than three months by treating clinical team
* Unable to consent to the study
* Unwilling to take part
* Subject has no fixed address
* Subject has previously been genotyped for PGx genes
* Subject has no current general practitioner
* Subject is, in the opinion of the Investigator, not suitable to participate in the study
* Estimated glomerular filtration rate (MDRD) of less than 15 ml/min per 1,73m2
* Patients with advanced liver failure (stage Child-Pugh C)
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT06956820
Study Brief:
Protocol Section:
NCT06956820